GW 275175X
GW 275175X is an inhibitor of the terminase complex involved in cleavage and packaging of the unit length DNA into the capsids. GW 275175X exhibits long plasma half-life. GW 275175X is a BDCRB derivative. GW 275175X exhibits anti-HCMV activity through inhibiting maturation of viral DNA.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 217950-62-4
- 화학식: C12H11BrCl2N2O4
- 분자량:398.04
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Chemical Information
-
CAS No. 217950-62-4
-
분자량 398.04
-
화학식 C12H11BrCl2N2O4
-
SMILES
O[C@H]1[C@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2Br)OC[C@@H](O)[C@H]1O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
순도&문서
References
[1]. Emery, V. C., & Hassan-Walker, A. F. (2002). Focus on new drugs in development against human cytomegalovirus. Drugs, 62(13), 1853-1858. [Content Brief]
[2]. Williams, S. L., et al., (2003). In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrobial agents and chemotherapy, 47(7), 2186-2192. [Content Brief]
[3]. McGregor, A., & Choi, K. Y. (2011). Cytomegalovirus antivirals and development of improved animal models. Expert opinion on drug metabolism & toxicology, 7(10), 1245-1265. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)